KIAA1539 activators encompass a diverse array of compounds that engage with several signaling pathways, ultimately potentiating the activity of this protein through distinct mechanisms. For instance, certain activators target the synthesis of cyclic AMP (cAMP), a crucial second messenger in cellular signaling. By activating adenylyl cyclase or inhibiting phosphodiesterases, these compounds increase intracellular cAMP levels, which could indirectly enhance KIAA1539 activity by engaging downstream components of the cAMP-dependent signaling cascade. Additionally, the use of cAMP analogs serves a similar purpose, mimicking the effects of natural cAMP and thereby potentially upregulating KIAA1539 activity within the cell. Furthermore, the modulation of protein kinase C (PKC) through specific activators influences a variety of cellular functions, and such modulation may alter the activity of KIAA1539 via PKC-mediated signaling pathways.
Other activators exert their effects by manipulating intracellular calcium levels. Calcium ionophores, for example, facilitate the influx of calcium ions, which could have a substantial impact on calcium-dependent signaling processes that indirectly affect the function of KIAA1539. Similarly, G-protein signaling is another avenue through which KIAA1539 activity could be modulated. Using non-hydrolyzable analogs of GTP, such as GTPγS, may lead to the persistent activation of G-proteins and the consequent engagement of signaling pathways that bear upon the activity of KIAA1539. In addition, compounds that alter the cellular redox state or interact with components of the Wnt/β-catenin signaling pathway may also modulate the activity of KIAA1539.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenergic agonist that elevates cAMP, indirectly promoting KIAA1539 activity via cAMP signaling. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-selective phosphodiesterase inhibitor, raises cAMP levels, possibly supporting KIAA1539 activation. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PKC activator that could modulate KIAA1539 activity by influencing protein kinase C-mediated signaling pathways. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
cAMP analog that could enhance KIAA1539 activity by mimicking the effects of cAMP in signaling pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Calcium ionophore that raises intracellular calcium, potentially affecting KIAA1539 through calcium-dependent mechanisms. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A calcium ionophore that could indirectly activate KIAA1539 by altering calcium signaling. | ||||||
Guanosine 5′-O-(3-thiotriphosphate) tetralithium salt | 94825-44-2 | sc-202639 | 10 mg | $465.00 | ||
Non-hydrolyzable GTP analog, could activate G-proteins and influence KIAA1539 activity downstream of G-protein signaling. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Adrenergic receptor agonist which increases cAMP levels, might indirectly activate KIAA1539 through cAMP-dependent pathways. | ||||||
Nicotinamide riboside | 1341-23-7 | sc-507345 | 10 mg | $411.00 | ||
NAD+ precursor that may enhance KIAA1539 function by influencing cellular redox states and related signaling pathways. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
GSK-3 inhibitor that could affect KIAA1539 by modifying Wnt signaling and associated downstream effects. | ||||||